EU approves Rasonque for previously treated metastatic pancreatic cancer
The European Commission has cleared Rasonque, an oral non-chemotherapy drug, for adults with metastatic pancreatic adenocarcinoma who have already had at least one line of systemic therapy. The approval applies across the EU plus Iceland, Norway and Liechtenstein, and covers patients with or without a RAS mutation. Revolution Medicines says it is now working with European health systems to open access.
- Original source: rarecancernews.com.
- The source published it on Nov 18, 2026 at 5:00 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The European Commission approved Rasonque (daraxonrasib) as a monotherapy for metastatic PDAC in patients who have received at least one prior line of systemic therapy. The decision covers all EU member states, plus Iceland, Norway and Liechtenstein, and applies to patients with or without an identified RAS tumor mutation. Revolution Medicines, the drug's maker, announced the clearance in a company press release.
The green light lands a few months after Rasonque won a similar U.S. approval. Revolution CEO Mark A. Goldsmith called the European decision a pivotal moment for people in the EU with metastatic pancreatic cancer and their families. He said the company is working with healthcare systems and stakeholders across the region to support timely access for eligible patients, according to the release.
Regulators based the approvals mainly on data from RASolute 302, a Phase 3 trial that tested Rasonque against standard chemotherapy in 500 adults with previously treated metastatic PDAC. Rasonque produced a median overall survival time of 13.2 months, versus 6.7 months for chemotherapy. The drug works by blocking RAS proteins, a group of signaling proteins that commonly contribute to abnormal cell growth in PDAC.
Common side effects listed in the U.S. prescribing information include rash, diarrhea, nausea, fatigue, vomiting, abdominal pain and swelling. Stomatitis, reduced appetite and hemorrhage also showed up commonly. Thomas Seufferlein, medical director at Ulm University Hospital in Germany, called the approval an important advance for patients with this aggressive and difficult-to-treat cancer, and said physicians have long had limited options beyond chemotherapy.
Revolution is now testing Rasonque as a potential first-line treatment in RASolute 303, an ongoing Phase 3 trial enrolling adults with newly diagnosed PDAC across Europe, Asia, Australia, Canada and Brazil. Participants are randomly assigned to Rasonque alone, Rasonque plus standard chemotherapy, or chemotherapy alone. The trial's main goal is to determine whether Rasonque slows disease progression and improves survival.
TopicsRasonque · daraxonrasib · Revolution Medicines · European Commission · Mark A. Goldsmith · Thomas Seufferlein · RASolute 302 · RASolute 303
Source: rarecancernews.com
Written by AI from verified reporting.
More stories
- Health & science theguardian.com 0 viewsE coli toxin colibactin flagged to MPs as prime suspect in under-50 bowel cancer rise
- Health & science medicalxpress.com Caught by @breakwater128 2 viewsFive-Day Antiviral Infusion Safe for Long COVID, ERASE Trial Finds
- Health & science dailycoffeenews.com 2 viewsFDA Pullplug on Methylene Chloride Use, Decaf Ban Fight Continues
- Health & science wam.ae 2 viewsUAE drug regulator: no medical ads without approval, influencer promos banned

